. MM-GBSA computation for tested compounds 
 Synthesis and characterization of compounds
Scheme S1 Synthesis of dissected LY2940680 analogs.
Scheme S2 Synthesis of TC114 analogs.
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CPM thermal shift assay
Engineered SMO with Flavodoxin (FLA, MW 16KD) 1 was constructed, expressed and purfied according to described procedure. 2 The N terminus was truncated at A52 and the C terminus was truncated at E559. Protein monodispersity was tested by analytical size-exclusion chromatography (aSEC). Typically, the aSEC profile showed a monodisperse peak. Each sample of the CPM thermal shift assay of SMO was performed in a total volume of 25 μL HPLC buffer (25 mM HEPES pH 7.5, 200 mM NaCl, 0.025% DDM / 0.005% CHS and 20 mM imidazole) comprised of 2 μg/mL CPM dye (N-[4-(7-diethylamino-4-methyl-3-coumarinyl)phenyl]maleimide) (Sigma), 0.01 mg/mL of purified SMO protein and 100 μM ligand. After incubation at 4 °C for 40 minutes, samples were heated in a controlled way with a ramp rate of 1 °C/min in a Rotor-Gene Q spectrofluorometer (Qiagen). The excitation wavelength was set at 365 nm, while the emission wavelength was 460 nm. Assays were performed over a temperature range starting from 25 °C and ending at 95 °C. All data were processed with GraphPad Prism program. A Bolzmann sigmoidal equation was fitted to the raw data to determine the melting temperature (Tm). 
Cell-based luciferase reporter assay
Antagonist activities for all new compounds were measured in a cell-based luciferase reporter assay as previously described with LY2940680 (in-house synthesized) as a reference [3] [4] . Briefly, the NIH3T3 cells that stably expressed firefly luciferase gene under the control of Gli responsive elements were cultured to confluency in 96-well plates using DMEM (Gibco) containing 10% (v/v) newborn calf serum (NCS, Gibco) and 175 μg/mL hygromycin (Gibco), and then treated with various concentrations of the indicated compounds in DMEM containing 0.5% NCS. After incubation at 37 °C for 1-2 hrs, final concentration of 100 nM SAG (in-house synthesized) was added and incubated at 37 °C for 24 h. Cellular firefly luciferase was measured with Bright-Glo ® Luciferase Assay System (Promega) using Envision 
Molecular Docking
The 2.8 Å crystal structure of SMO with PDB code 5V56 was used for docking. 1 The structure was processed by Protein Preparation Wizard in Schrödinger Suite 2015-4 before docking. 5 All compounds were prepared by Ligprep with OPLS3 force field.
Glide XP was then used for SMO docking. 6 The pose of green colored moiety (Fig. S4) of the co-crystallized ligand TC114 in PDB 5V56, which is shared by all compounds, was used as reference in Glide XP docking, with RMSD cutoff of all heavy atoms in the moiety setting at 0.3 Å. The output of Glide XP docking was saved as a pose viewer file for Prime MM-GBSA relative binding affinity calculation. 7 During Prime MM-GBSA calculation, all atoms within 5 Å of ligand in each ligand-receptor complex was optimized. 
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e-f. g. General procedure for HATU mediated couplings for the production of TC114
analogs.
To a solution of benzoic acid S7 (0.34 mmol) in 3 mL CH 2 Cl 2 , secondary amine S6 and brine sequentially, dried over Na 2 SO 4 . After filtration, the solution was concentrated in vacuum and the crude product was purified by flash column chromatography on silica gel to yield 1 as colorless solid (82 mg, 62%). hours, the solvent and excess TFA was removed in vacuo. The residue was neutralized with 1M aqueous sodium hydroxide and extracted three times with EtOAc. The combined organic layers were washed with brine, dried over anhydrous Na 2 SO 4. After evaporation, the crude product was used without further purification.
N-methyl-N-(1-(4-(1-methyl-1H-pyrazol-5-yl)phthalazin-1-yl)piperidin-4-yl)-4-nitrobenzamide (5). Colorless solid, isolated yield 91% (75 mg
4-fluoro-N-methyl-N-(1-(4-(1-methyl-1H-pyrazol-5-yl)phthalazin-1-yl)piperidin-4-yl)benzamide (6). Colorless solid, isolated yield 91% (42 mg
4-(dimethylamino)-N-methyl-N-(1-(4-(1-methyl-1H-pyrazol-5-yl)phthalazin-1-yl)piperidin-4-yl)benzamide (10
N N N N O SO 2 Me 11 N N N-methyl-N-(1-(4-(1-methyl-1H-pyrazol-5-yl)phthalazin-1-yl)piperidin-4-yl)-4- (methylsulfonyl)
4-(methyl(1-(4-(1-methyl-1H-pyrazol-5-yl)phthalazin-1-yl)piperidin-4-yl)carbamoyl)benzoate (14
N O N N N N N 19 O N-methyl-N-(1-(4-(1-methyl-1H-pyrazol-5-yl)phthalazin-1-yl)piperidin-4-yl)-4-
N-methyl-N-(1-(4-(1-methyl-1H-pyrazol-5-yl)phthalazin-1-yl)piperidin-4-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (S15
4-hydroxy-N-methyl-N-(1-(4-(1-methyl-1H-pyrazol-5-yl)phthalazin-1-yl)piperidin-4-yl)benzamide (S17
Synthesis of N-(1-(4-chlorophthalazin-1-yl)piperidin-4-yl)-4-fluoro-N-methyl-2-(trifluoromethyl)benzamide (4).
To a solution of S8 (26 mg, 0.13 mmol) in DCM (1 mL), was added HATU (53 mg, 0.14 mmol). After stirring for 1 hour at room temperature, 1-(4-chlorophthalazin-1-yl)-N-methylpiperidin-4-amine (35 mg, 0.13 mmol) and DIPEA (45 μL, 0.25 mmol) were added to the reaction mixture. After stirring for 2 hours, the reaction mixture was quenched by saturated NH 4 Cl and extracted three times with EtOAc. The combined organic layers were washed with brine, dried over anhydrous Na 2 SO 4. After evaporation, the crude product was purified by preparative TLC (DCM : MeOH = 20 : 1) to afford the product 4 as colorless solid (55 mg, 93%). 1 
S11
Synthesis of tert-butyl (1-(4-bromonaphthalen-1-yl)piperidin-4-yl)(methyl)carbamate (S11).
A solution of Pd 2 (dba) 3 (46 mg, 0.05 mmol), BINAP (62 mg. 0.1 mmol) in toluene (5 mL) was degassed with N 2 and then heated for 15 minutes. The reaction mixture was cooled to room temperature before t-BuOK (224 mg, 2.0 mmol), S10 (285 mg, 1.0 mmol), S3 (321 mg, 1.5 mmol) were added. The resulting mixture was heated to 110 °C. After stirring for 16 hours, the reaction mixture was cooled to room temperature. After removing the solvent, the residue was diluted with water and extracted three times with EtOAc. The combined organic layers were washed with brine, dried over anhydrous Na 2 SO 4. After evaporation, the crude product was purified by flash column chromatography (PE : EA = 10 : 1) on silica gel to afford the product S11 as colorless solid (368 mg, 88 %). 1 
S12
Synthesis of N-methyl-1-(4-(1-methyl-1H-pyrazol-5-yl)naphthalen-1-yl)piperidin-4-amine (S12).
A solution of Na 2 CO 3 (95 mg, 0.88 mmol), S5 (110 mg, 0.53 mmol), S11 (184 mg, 0.44 mmol) in 1,4-dioxane (2 mL), H 2 O (0.5 mL) was degassed with N 2 for 15 minutes. Then Pd(PPh 3 ) 4 (25 mg, 0.02 mmol) was added to the reaction mixture and the mixture was heated to 90 °C. After stirring for 6 hours, the reaction mixture was cooled to room temperature, diluted with water and extracted three times with EtOAc.
The combined organic layers were washed with brine, dried over anhydrous Na 2 SO 4. After evaporation, the crude product was purified by flash column chromatography (PE : EA = 2 : 1) on silica gel to afford the product (110 mg, 60 %) as colorless solid. 1 The combined organic layers were washed with brine, dried over anhydrous Na 2 SO 4. After evaporation, the crude product S12 was used without further purification.
Synthesis of 4-fluoro-N-methyl-N-(1-(4-(1-methyl-1H-pyrazol-5-yl)naphthalen-1-yl)piperidin-4-yl)-2-(trifluoromethyl)benzamide (3).
To a solution of S8 (23 mg, 0.11 mmol) in DCM (1 mL), was added HATU (46 mg, 0.12 mmol). After stirring for 1 hour at room temperature, S12 (32 mg, 0.1 mmol) and DIPEA (36 μL, 0.2 mmol) were added to the reaction mixture. After stirring for 2 hours, the reaction mixture was quenched by saturated NH 4 Cl and extracted three times with EtOAc. The combined organic layers were washed with brine, dried over anhydrous Na 2 SO 4. After evaporation, the crude product was purified by preparative TLC (DCM : MeOH = 20 : 1) to afford the product 3 as colorless solid (45 mg, 88%). 1 N-methyl-N-(1-(4-(1-methyl-1H-pyrazol-5-yl) phthalazin-1-yl)piperidin-4-yl)benzamide (7) . To a solution of 5 (75 mg, 0.16 mmol) in THF (0.5 mL), MeOH (0.3 mL) and H 2 O (0.2 mL), was added iron powder (38 mg, 0.64 mmol) and NH 4 Cl (35 g, 0.64 mmol). The reaction mixture was stirred at 85 °C for 2 hours.
The mixture was then cooled to room temperature and filtered through a pad of celite.
The filtrate was concentrated in vacuo. The residue was diluted with water and extracted three times with EtOAc. The combined organic phase was washed with brine, dried over anhydrous Na 2 SO 4 and concentrated in vacuo. Finally, the crude product was purified by flash column chromatography (DCM : MeOH = 30 : 1) on silica gel to afford the product 7 as colorless solid (56 mg, 80%). 1 
Synthesis of (4-(methyl(1-(4-(1-methyl-1H-pyrazol-5-yl)phthalazin-1-yl)piperidin-4-yl)carbamoyl)phenyl)glycine (8)
.
Synthesis of 4-(chlorosulfonyl)benzoyl chloride (S19
Synthesis of 4-(methyl(1-(4-(1-methyl-1H-pyrazol-5-yl)phthalazin-1-yl)piperidin-4-yl)carbamoyl)benzenesulfonic acid (12).
To a solution of S14 (30 mg, 0.057 mmol) in 1,4-dioxane (0.5 mL) and H 2 O (0.5 mL), was added NaOH (5 mg, 0.11 mmol) at 0 °C.
The mixture was then heated to 65 °C and stirred for 2 hours. Then the mixture was cooled to room temperature and neutralized with ion-exchange resin (amberlite TM IR120). The solid was filtered and the filtrate was concentrated in vacuo. The crude residue was purified by flash column chromatography (DCM : MeOH = 30 : 1) on silica gel to afford the product 12 as colorless solid (15 mg, 52 %). 1 
Synthesis of N-methyl-N-(1-(4-(1-methyl-1H-pyrazol-5-yl)phthalazin-1-yl)piperidin-4-yl)-4-sulfamoylbenzamide (13).
To a solution of S14 (32 mg, 0.06 mmol) in THF (0.5 ml), was added 25% aqueous ammonia (10 μL). After stirring for 1 hour at room temperature, the reaction mixture was concentrated in vacuo. The crude product was purified by preparative TLC (DCM : MeOH = 10 : 1) to afford the product 13 as colorless solid (16 mg, 53%). 1 
Synthesis of (4-(methyl(1-(4-(1-methyl-1H-pyrazol-5-yl)phthalazin-1-yl)piperidin-4-yl)carbamoyl)phenyl)boronic acid (17).
To a solution of S15 (25 mg, 0.045 mmol) in THF (0.4 mL) and H 2 O (0.1 mL), was added NaIO 4 (29 mg, 0.14 mmol). After stirring at room temperature for 30 minutes, 3N HCl (0.05 mL) was added to the mixture and allowed to stir for 4 hours. The mixture was diluted with EtOAc and washed with brine, dried over anhydrous Na 2 SO 4 . The organic layer was concentrated in vacuo. Finally, the crude product was purified by preparative TLC (DCM : MeOH = 10 : 1) to afford the product 17 as colorless solid (15 mg, 70%). 1 
Synthesis of N-methyl-N-(1-(4-(1-methyl-1H-pyrazol-5-yl)phthalazin-1-yl)piperidin-4-yl)-4-(2-oxoethyl)benzamide (18).
To a solution of S16 (44 mg, 0.094 mmol) in DCM (1 mL), was added Dess-Martin periodinane (60 mg, 0.14 mmol). After stirring at room temperature for 1 hour, the reaction mixture was quenched by saturated NaHCO 3 and extracted three times with EtOAc. The combined organic layers were washed with brine, dried over anhydrous Na 2 SO 4. After evaporation, the crude product was purified by preparative TLC (DCM : MeOH = 10 : 1) to afford the product 18 as colorless solid (17 mg, 39%). 1 (20) . To a solution of S17 (20 mg, 0.05 mmol) in DMF (0.5 ml), was added Cs 2 CO 3 (30 mg, 0.09 mmol) and benzyl bromide (11 μL, 0.09 mmol). After stirring at room temperature for 12 hours, the mixture was diluted with water and extracted three times with EtOAc. The combined organic layers were washed with brine, dried over anhydrous Na 2 SO 4. After evaporation, the crude product was purified by preparative TLC (DCM : MeOH = 10 : 1) to afford the product 20 as colorless solid (18 mg, 75%). 1 N-methyl-N-(1-(4-(1-methyl-1H-pyrazol-5-yl)phthalazin-1-yl) 
Synthesis of 4-(benzyloxy)-N-methyl-N-(1-(4-(1-methyl-1H-pyrazol-5-yl)phthalazin-1-yl)piperidin-4-yl)benzamide
Synthesis of 4-(benzyloxy)-N-methyl-N-(1-(4-(1-methyl-1H-pyrazol-5-yl)phthalazin-1-yl)piperidin-4-yl)-2-(trifluoromethyl)benzamide (S1).
To a solution of benzyl alcohol (30 μL, 0.29 mmol) in anhydrous DMF (0.5 mL), was added 60% NaH (19 mg, 0.47 mmol) at 0 °C. After stirring for 20 minutes, LY2940680 (30 mg, 0.059 mmol) was added to the mixture and the mixture was heated to 120 °C. After stirring for 2 hours, the mixture was cooled to room temperature, diluted with water and extracted three times with EtOAc. The combined organic layers were washed with brine, dried over anhydrous Na 2 SO 4. After evaporation, the crude product was purified by preparative TLC (DCM : MeOH = 20 : 1) to afford the product S1 as colorless solid (30 mg, 86%). 1 H NMR (500 MHz, CDCl 3 ), major rotamer δ (ppm) 1.78-2.26 (m, 4H, CH 2 ), 2.77 (s,
